Stock Events

Stock Events

Voyager Therapeutics 

$3.74
59
-$0.06-1.58% Today

Statistics

Day High
3.85
Day Low
3.73
52W High
5.33
52W Low
2.73
Volume
21,055,354
Avg. Volume
-
Mkt Cap
207.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.59
-0.45
-0.3
-0.16
Expected EPS
-0.489513
Actual EPS
N/A

Financials

-81.25%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
160MRevenue
-130MNet Income

Analyst Ratings

25Average Price Target
The highest estimate is 25.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VYGR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap28.61B
Biogen focuses on neurological diseases, directly competing in Voyager's therapeutic areas, including gene therapy.
Sarepta Therapeutics
SRPT
Mkt Cap1.77B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, similar to Voyager's mission.
PTC Therapeutics
PTCT
Mkt Cap5.71B
PTC Therapeutics is involved in the development of genetically targeted therapies, including for neurological disorders, competing with Voyager.
Novartis
NVS
Mkt Cap290.05B
Novartis has a strong presence in gene therapy, particularly with its acquisition of AveXis, making it a direct competitor in the gene therapy space.
Pfizer
PFE
Mkt Cap147.62B
Pfizer has invested heavily in gene therapy for rare diseases, positioning it as a competitor in the same field as Voyager.
Abeona Therapeutics
ABEO
Mkt Cap310.05M
Abeona Therapeutics focuses on developing gene and cell therapies for serious diseases, making it a competitor in the gene therapy market.

About

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Show more...
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Employees
172
Country
United States
ISIN
US92915B1061

Listings

STU
DE
VT6.STU
MU
DE
VT6.MU
MX
MX
VYGR.MX
XNAS
US
VYGR

0 Comments

Share your thoughts

FAQ

What is Voyager Therapeutics stock price today?▼
The current price of VYGR is $3.74 USD — it has decreased by -1.58% in the past 24 hours. Watch Voyager Therapeutics stock price performance more closely on the chart.
What is Voyager Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Voyager Therapeutics stocks are traded under the ticker VYGR.
Is Voyager Therapeutics stock price growing?▼
VYGR stock has risen by +7.04% compared to the previous week, the month change is a -1.72% fall, over the last year Voyager Therapeutics has showed a +27.57% increase.
What is Voyager Therapeutics market cap?▼
Today Voyager Therapeutics has the market capitalization of 207.94M
When is the next Voyager Therapeutics earnings date?▼
Voyager Therapeutics is going to release the next earnings report on July 30, 2026.
What were Voyager Therapeutics earnings last quarter?▼
VYGR earnings for the last quarter are -0.47 USD per share, whereas the estimation was -0.55 USD resulting in a +14.68% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Voyager Therapeutics revenue for the last year?▼
Voyager Therapeutics revenue for the last year amounts to 160M USD.
What is Voyager Therapeutics net income for the last year?▼
VYGR net income for the last year is -130M USD.
How many employees does Voyager Therapeutics have?▼
As of May 26, 2026, the company has 172 employees.
In which sector is Voyager Therapeutics located?▼
Voyager Therapeutics operates in the Health & Wellness sector.
When did Voyager Therapeutics complete a stock split?▼
Voyager Therapeutics has not had any recent stock splits.
Where is Voyager Therapeutics headquartered?▼
Voyager Therapeutics is headquartered in Lexington, United States.